title: ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis.
abstract: BACKGROUND
  Antineutrophil cytoplasmic autoantibodies (ANCA) are presumed to reflect disease-activity and to be useful for guidance of immunosuppressive therapy of ANCA-associated systemic vasculitis (AASV), but with respect to conventional ANCA assays this is controversial. ANCA titres, measured in the IgG3 subclass and modern capture ELISAs, have been said to be superior predictors of relapses of AASV.
  
  
  METHODS
  In this retrospective study serial measurements of ANCA parameters and soluble CD14 (sCD14) were performed in 169 consecutive sera over a median of 21 months in 18 patients with AASV and related to disease activity, assessed by Birmingham Vasculitis Activity Score (BVAS) for new or deteriorated (BVAS1), and for chronic disease activity (BVAS2). Fourteen patients had Wegener's granulomatosis (WG) and were C-ANCA positive with Pr 3-antibodies and four patients had microscopic polyangiitis (MPA) with P-ANCA and MPO-antibodies. In WG patients ANCA by IIF, Pr 3-ELISA for IgG, IgG1, IgG3, IgG4 and sCD14 were measured, as well as capture ELISA for Pr 3, and in MPA patients ANCA by IIF, MPO-ELISA for IgG and IgG1, IgG3, IgG4, and sCD14 respectively. In eight patients, data collection started at diagnosis, in 10 patients at remission.
  
  
  RESULTS
  The parameters predicted neither the nine major relapses (increase of immunosuppression necessary), nor the 26 minor relapses (increase of BVAS1>2) with sufficient sensitivity (>80%) or specificity (> 90%90%), and they also failed to predict relapses within the following 2 months. ANCA-IgG3 and capture ELISA for Pr 3 were not advantageous for prediction of relapses (sensitivity 0.45 and 0.19 respectively), and sCD14 remained elevated in all samples irrespective of disease activity.
  
  
  CONCLUSIONS
  There is no rationale for serial measurements of ANCA in AASV. For changes of therapy, the ANCA parameters should only be used in conjunction with clinical information.
authors.affiliation: Fifth Medical Clinic (Nephrology, Endocrinology), University-Clinic Mannheim, Faculty of Clinical Medicine of the University of Heidelberg, Mannheim, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Nowack
authors.forename: I
authors.initials: I
authors.lastname: Grab
authors.forename: L F
authors.initials: LF
authors.lastname: Flores-Suarèz
authors.forename: P
authors.initials: P
authors.lastname: Schnülle
authors.forename: B
authors.initials: B
authors.lastname: Yard
authors.forename: F J
authors.initials: FJ
authors.lastname: van der Woude
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D018950:Lipopolysaccharide Receptors / Q000032:analysis*; D053146:Myeloblastin; D011379:Prognosis; D020033:Protein Isoforms / Q000097:blood; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012697:Serine Endopeptidases / Q000378:metabolism; D012720:Severity of Illness Index; D012995:Solubility; D014657:Vasculitis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D007074:Immunoglobulin G; D018950:Lipopolysaccharide Receptors; D020033:Protein Isoforms; D012697:Serine Endopeptidases; D053146:Myeloblastin